Table 2 Evidence Opposing Cognitive Impairment
Study | Study Design | Statin | Participants | Findings/Relevance |
|---|---|---|---|---|
Ott BR, et al., 2015, [5] | Systematic review and meta-analysis | All | 56,655 | Statin therapy was not associated with cognitive impairment in RCTs. |
Richardson K, et al., 2013, [21] | Systematic review | All | 56,043 | Larger and better-designed studies are needed to draw unequivocal conclusions about the effect of statins on cognition. Published data do not suggest an adverse effect of statins on cognition; however, the strength of available evidence is limited, particularly with regard to high-dose statins. |
Benito-LeĂłn J, et al., 2010, [22] | Population based study | Ator, flu, lova, prav, sim, | 548 | Statin users and controls performed similarly on neuropsychological tests. |
Lilly SM, et al., 2014, [23] | Retrospective database investigational study | Ator, flu, lova, prava, rosu, sim | 13,626 | Non-persistent statin users had a greater risk of being diagnosed with schizophrenia/psychosis and cognitive disorders compared with persistent users. |
Swiger KJ, et al., 2013, [24] | Systematic review and meta-analysis | All | 23,541 | In patients without baseline cognitive dysfunction, the results of the available studies are most compatible with no significant short-term cognitive detriments related to statin therapy, whereas long-term data suggest a beneficial role in the prevention of dementia. |
McGuiness B, et al., 2016, [11] | Systematic review | Prava, Sim | 26,340 | There were no differences between statin and placebo groups on five different cognitive tests. |